Cerus - CERS Stock Forecast, Price & News

0 equities research analysts have issued 1-year price objectives for Cerus' stock. Their CERS share price forecasts range from $6.00 to $6.00. On average, they expect the company's share price to reach $6.00 in the next year. This suggests a possible upside of 63.5% from the stock's current price.
View analysts price targets for CERS or view top-rated stocks among Wall Street analysts.

Cerus' stock was trading at $6.81 at the beginning of 2022. Since then, CERS stock has decreased by 46.1% and is now trading at $3.67.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our CERS earnings forecast.

Cerus Co. (NASDAQ:CERS) posted its quarterly earnings data on Tuesday, November, 2nd. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03. The biotechnology company earned $36.13 million during the quarter, compared to the consensus estimate of $31.60 million. Cerus had a negative net margin of 24.24% and a negative trailing twelve-month return on equity of 48.32%. During the same quarter last year, the company posted ($0.08) EPS.

Cerus updated its FY 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $160.00 million-$162.00 million, compared to the consensus revenue estimate of $173.50 million.

15 employees have rated Cerus Chief Executive Officer William M. (Obi) Greenman on Glassdoor.com. William M. (Obi) Greenman has an approval rating of 35% among the company's employees. This puts William M. (Obi) Greenman in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cerus investors own include Rite Aid (RAD), SCYNEXIS (SCYX), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Pfizer (PFE), Immunomedics (IMMU), Exelixis (EXEL), Novavax (NVAX) and NVIDIA (NVDA).

Cerus trades on the NASDAQ under the ticker symbol "CERS."

Cerus' stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (9.52%), BlackRock Inc. (6.89%), Vanguard Group Inc. (5.89%), Sumitomo Mitsui Trust Holdings Inc. (4.14%), State Street Corp (2.75%) and Senvest Management LLC (2.50%). Insiders that own company stock include Carol Moore, Chrystal Menard, Daniel N Swisher Jr, Gail Schulze, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin, Timothy B Anderson, Timothy L Moore, Vivek K Jayaraman, Vivek K Jayaraman and William Mariner Greenman.
View institutional ownership trends.

Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CERS stock can currently be purchased for approximately $3.67.

Cerus (NASDAQ:CERS) has a market capitalization of $651.13 million and generates $130.86 million in revenue each year. The biotechnology company earns $-54,380,000.00 in net income (profit) each year or ($0.22) on an earnings per share basis.

The company employs 631 workers across the globe.

Cerus' mailing address is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. The official website for the company is www.cerus.com. The biotechnology company can be reached via phone at (925) 288-6000, via email at ir@cerus.com, or via fax at 925-288-6001.